05:04:33 EDT Mon 15 Aug 2022
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Avicanna Inc
Symbol AVCN
Shares Issued 41,271,574
Close 2021-09-13 C$ 0.91
Recent Sedar Documents

Avicanna notes revocation of CTO

2021-09-13 09:11 ET - News Release

Mr. Aras Azadian reports

AVICANNA ANNOUNCES REVOCATION OF CEASE TRADE ORDER

Avicanna Inc. has noted that the failure-to-file cease trade order issued by the Ontario Securities Commission on June 11, 2021, has been revoked, effective Sept. 10, 2021.

The company will work with the Toronto Stock Exchange on a reinstatement of trading of its common shares, which were suspended from trading on June 11, 2021, as a result of the CTO.

The company has filed the following periodic disclosure documents, bringing its continuous disclosure record up to date in accordance with applicable securities law:

  • Annual filings in respect of the year ended Dec. 31, 2020, consisting of audited annual financial statements for the year ended Dec. 31, 2020, management discussion and analysis relating to the audited annual financial statements for the year ended Dec. 31, 2020, annual information form for the year ended Dec. 31, 2020, and certification of the foregoing as required by National Instrument 52-109, Certification of Disclosure in Issuers' Annual and Interim Filings;
  • Interim filings in respect of the period ended March 31, 2021, consisting of interim financial statements for the period ended March 31, 2021, management discussion and analysis relating to the interim financial statements for the period ended March 31, 2021, and certification of the foregoing as required by NI 52-109;
  • Interim filings in respect of the period ended June 30, 2021, consisting of interim financial statements for the period ended June 30, 2021, management discussion and analysis relating to the interim financial statements for the period ended June 30, 2021, and certification of the foregoing as required by NI 52-109.

Investor webinar

On Tuesday, Sept. 14, 2021, at 2 p.m. EDT, Avicanna's chief executive officer, Aras Azadian, will host an investor webinar, providing the latest company updates followed by a live question-and-answer session.

About Avicanna Inc.

Avicanna is a commercial-stage Canadian biopharmaceutical company and an established leader in cannabinoid research, development and evidence-based products for the global consumer, medical and pharmaceutical market segments. Avicanna conducts its research in Canada including its R&D headquarters in the Johnson & Johnson innovation centre, JLABS @ Toronto, Canada, located in the MaRS Discovery District, and in collaboration with leading Canadian academic and medical institutions. Avicanna has established an industry-leading scientific platform, including advanced R&D and clinical development, that has led to the commercialization of over 20 products across four main market segments:

  • Rho Phyto: These medical and wellness products are an advanced line of pharmaceutical-grade cannabis products containing varying ratios of CBD and THC. The product portfolio contains a full formulary of products, including oral, sublingual, topical and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by preclinical data. These products are developed using pharmaceutical drug development processes and are supported with preclinical data. The advanced formulary is marketed with consumer, patient and medical community education and training.
  • Pura H&W/Pura Earth: These registered, clinically tested cosmetic products include a portfolio of functional CBD consumer derma-cosmetic and topical products.
  • Aureus: As a part of Avicanna's vertical integration based out of Santa Marta, Colombia, its supply chain business units are primarily dedicated to providing consistent source of cannabinoid raw materials for Avicanna and its global partners' food, cosmetic, medical and pharmaceutical needs. Aureus-branded products are cultivated, extracted and manufactured by Avicanna's subsidiaries in Colombia, where they benefit from optimal environmental conditions to produce cannabinoid active pharmaceutical ingredients economically, organically and sustainably and include a range of CBD, THC and rare cannabinoids such as CBG (cannabigerol) extracts and standardized seeds. The company is well positioned to be a global supplier of cannabinoid raw materials demand and has already successfully exported its products to over 10 countries in four continents.
  • Pharmaceutical pipeline: Leveraging the company's scientific platform, vertical integration and real-world evidence, Avicanna has established a pipeline of indication-specific cannabinoid-based drug candidates that are in various stages of clinical development and commercialization. Avicanna's drug candidates are in the preclinical stage and the company is dedicated to providing solutions for unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders.

We seek Safe Harbor.

© 2022 Canjex Publishing Ltd. All rights reserved.